AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron…
Equasens: availability of AGM preparatory materials
Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY…
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with…